Found 4 articles for: "baricitinib"
Baricitinib-Related Adverse Events in Alopecia Areata and Rheumatoid Arthritis: A Comparative Study
March 2026 | Volume 25 | Issue 3 | Features | 286 | Copyright © March 2026
Alopecia Universalis: Never Give Up?
March 2025 | Volume 24 | Issue 3 | Case Reports | 316 | Copyright © March 2025
Introduction: Oral Janus kinase inhibitors (JAKi) have demonstrated significant promise in hair regrowth for severe alopecia areata. Baricitinib and ritlecitinib are two medicati...
Read MoreReview of Baricitinib in the Treatment of Alopecia Areata
September 2023 | Volume 22 | Issue 9 | Original Article | 935 | Copyright © September 2023
Background: Alopecia areata (AA) is a debilitating autoimmune disease that results in non-scarring hair loss. Baricitinib is the Food and Drug Administration (FDA) approved treat...
Read MoreOff-Label Use of Baricitinib in Dermatology
August 2023 | Volume 22 | Issue 8 | Original Article | 795 | Copyright © August 2023
The current US Food and Drug Administration (FDA) indications for baricitinib include alopecia areata, rheumatoid arthritis, and COVID-19. However, increasing evidence indicates that baricitinib ...
Read More
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.